Your session is about to expire
← Back to Search
RAS Inhibitor
Blood Pressure Medications for COVID-19
Phase 3
Waitlist Available
Led By Peter Liu, MD
Research Sponsored by Ottawa Heart Institute Research Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 40 years old or greater if outpatient
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
This trial will test whether drugs that treat high blood pressure can also help treat Covid-19 in high-risk patients.
Who is the study for?
Adults diagnosed with COVID-19 can join this trial. Hospitalized patients must be 18 or older, while non-hospitalized ones need to be at least 40. They should have confirmed COVID-19 within the last month but not suffer from severe low blood pressure, high potassium levels, certain kidney issues, or conditions that make ACEi/ARB use unsafe.Check my eligibility
What is being tested?
The study is testing if drugs called RAS inhibitors—specifically ACE inhibitors (ACEi) and Angiotensin II Receptor Blockers (ARB)—can improve outcomes for COVID-19 patients by reducing ICU stays, ventilator needs or death. It also compares the effectiveness of ACEi versus ARB on long-term quality of life.See study design
What are the potential side effects?
Possible side effects include dizziness or lightheadedness due to low blood pressure, elevated potassium levels which can affect heart rhythm, and potential kidney function changes. These medications may not suit those with a history of swelling caused by drug reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 40 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Death
Hospitalizations
ICU admission
+3 moreSecondary outcome measures
All cause hospitalization
Cardiovascular mortality
Days alive and out of hospital
+3 moreTrial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: ARB treatmentExperimental Treatment1 Intervention
The physician will initiate any ARB and dose at their discretion.
Group II: ACEi treatmentExperimental Treatment1 Intervention
The physician will initiate any ACE inhibitor and dose at their discretion.
Group III: No Treatment (Standard of Care)Active Control1 Intervention
Participants will be treated as per standardized care pathway according to province/state and institutional guidelines. Physicians will be reminded not to start ACEi or ARB throughout admission or to outpatients until active study participation is complete at 28 days post symptoms.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Angiotensin II
FDA approved
Find a Location
Who is running the clinical trial?
Ottawa Heart Institute Research CorporationLead Sponsor
188 Previous Clinical Trials
91,281 Total Patients Enrolled
Peter Liu, MDPrincipal InvestigatorOttawa Heart Institute Research Corporation
5 Previous Clinical Trials
2,710 Total Patients Enrolled
Media Library
Research Study Groups:
This trial has the following groups:- Group 1: No Treatment (Standard of Care)
- Group 2: ACEi treatment
- Group 3: ARB treatment
Awards:
This trial has 3 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this research project still recruiting participants?
"Yes, the clinical trial is still recruiting patients. According to information on clinicaltrials.gov, the study was first posted on 1/27/2021 and last updated on 9/23/2022."
Answered by AI
What other scientific Angiotensin II Receptor Blocker research has been published?
"Angiotensin II Receptor Blockers was first studied in 2008 at the George E Wahlen VA Medical Center. As of now, there have been 62 completed studies with 30 more clinical trials underway. The majority of these active studies are based out of Ottawa, Ontario."
Answered by AI
Has the FDA cleared Angiotensin II Receptor Blockers for use?
"Angiotensin II Receptor Blockers are generally considered safe, as this medication has undergone Phase 3 clinical trials. This means that not only is there some evidence supporting its efficacy, but also that it has been rigorously tested for safety concerns."
Answered by AI
How many test subjects are included in the research?
"The clinical trial is currently looking for participants. Based on the information provided by clinicaltrials.gov, 1155 patients are needed from 2 different centres."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger